RE:RE:RE:RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now HCal,
In retrospect, I cannot disagree with the last half of your post. Yes, I have been here a very long time. Yes it would be better to be buying now for the first time.
But, I would say the incremental improvements shown in the first panc trial (n=3) will very exciting for panc patients if we see something like that next month.
The biomarker helps us find those who have immune systems that are viabile, which has got to be important for trials and marketing. Yes it would cut down the potential market, but it sure would motivate those who fit the biomarker profile.
In the end, I own a great deal here as well although not as much as you do. The value of the company is far more than its current market cap. It is a long wait and some longish odds for a huge potential payoff. If we get a share price of over $20, you and I could likely retire.